Incidental prostate cancer revisited: Early outcomes after holmium laser enucleation of the prostate

Rafael Nunez, Kimberly J. Hurd, Brie N. Noble, Erik P Castle, Paul E. Andrews, Mitchell R Humphreys

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Incidental prostate cancer (PCa) after treatment of benign prostate hyperplasia (BPH) is becoming less common. This is a result of the changing patterns of BPH treatment. The purpose of the present research was to re-examine the clinical outcomes and importance of cT1a and cT1b PCa in a contemporary cohort after holmium laser enucleation of the prostate (HoLEP). All patients with newly diagnosed PCa after HoLEP were retrospectively identified. Pre- and postoperative prostate-specific antigen (PSA), biopsy history, pathological features and disease progression were examined. Patients were matched to a control group with benign pathology for outcome comparisons. The database consisted of 240 consecutive patients, aged 52-90years with prostate sizes from 25 to 375cm3. A total of 28 patients were identified with incidental PCa (14 cT1a and 14 cT1b). Median follow up was 11months and 13months for cT1a and cT1b, respectively. Hospitalization time, catheterization time, complications and functional outcomes were similar. Three patients with cT1b required additional treatment as a result of PSA progression. All other cancers are being closely followed. The functional benefits of HoLEP are well established. The incidental PCa detection rate of 11.7% shows the potential benefit of pathological analysis. Just 10.7% of these patients received additional treatment, but this might be significant as these patients would otherwise go untreated. The impact on disease-specific survival and progression requires a longer follow up.

Original languageEnglish (US)
Pages (from-to)543-547
Number of pages5
JournalInternational Journal of Urology
Volume18
Issue number7
DOIs
StatePublished - Jul 2011
Externally publishedYes

Fingerprint

Solid-State Lasers
Prostate
Prostatic Neoplasms
Prostate-Specific Antigen
Hyperplasia
Therapeutics
Catheterization
Disease Progression
Hospitalization
History
Databases
Pathology
Biopsy
Control Groups
Survival
Research
Neoplasms

Keywords

  • Benign prostate hyperplasia
  • Holmium laser enucleation of the prostate
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Incidental prostate cancer revisited : Early outcomes after holmium laser enucleation of the prostate. / Nunez, Rafael; Hurd, Kimberly J.; Noble, Brie N.; Castle, Erik P; Andrews, Paul E.; Humphreys, Mitchell R.

In: International Journal of Urology, Vol. 18, No. 7, 07.2011, p. 543-547.

Research output: Contribution to journalArticle

Nunez, Rafael ; Hurd, Kimberly J. ; Noble, Brie N. ; Castle, Erik P ; Andrews, Paul E. ; Humphreys, Mitchell R. / Incidental prostate cancer revisited : Early outcomes after holmium laser enucleation of the prostate. In: International Journal of Urology. 2011 ; Vol. 18, No. 7. pp. 543-547.
@article{281fceea1db84fb99c8aa62610ccae54,
title = "Incidental prostate cancer revisited: Early outcomes after holmium laser enucleation of the prostate",
abstract = "Incidental prostate cancer (PCa) after treatment of benign prostate hyperplasia (BPH) is becoming less common. This is a result of the changing patterns of BPH treatment. The purpose of the present research was to re-examine the clinical outcomes and importance of cT1a and cT1b PCa in a contemporary cohort after holmium laser enucleation of the prostate (HoLEP). All patients with newly diagnosed PCa after HoLEP were retrospectively identified. Pre- and postoperative prostate-specific antigen (PSA), biopsy history, pathological features and disease progression were examined. Patients were matched to a control group with benign pathology for outcome comparisons. The database consisted of 240 consecutive patients, aged 52-90years with prostate sizes from 25 to 375cm3. A total of 28 patients were identified with incidental PCa (14 cT1a and 14 cT1b). Median follow up was 11months and 13months for cT1a and cT1b, respectively. Hospitalization time, catheterization time, complications and functional outcomes were similar. Three patients with cT1b required additional treatment as a result of PSA progression. All other cancers are being closely followed. The functional benefits of HoLEP are well established. The incidental PCa detection rate of 11.7{\%} shows the potential benefit of pathological analysis. Just 10.7{\%} of these patients received additional treatment, but this might be significant as these patients would otherwise go untreated. The impact on disease-specific survival and progression requires a longer follow up.",
keywords = "Benign prostate hyperplasia, Holmium laser enucleation of the prostate, Prostate cancer",
author = "Rafael Nunez and Hurd, {Kimberly J.} and Noble, {Brie N.} and Castle, {Erik P} and Andrews, {Paul E.} and Humphreys, {Mitchell R}",
year = "2011",
month = "7",
doi = "10.1111/j.1442-2042.2011.02776.x",
language = "English (US)",
volume = "18",
pages = "543--547",
journal = "International Journal of Urology",
issn = "0919-8172",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - Incidental prostate cancer revisited

T2 - Early outcomes after holmium laser enucleation of the prostate

AU - Nunez, Rafael

AU - Hurd, Kimberly J.

AU - Noble, Brie N.

AU - Castle, Erik P

AU - Andrews, Paul E.

AU - Humphreys, Mitchell R

PY - 2011/7

Y1 - 2011/7

N2 - Incidental prostate cancer (PCa) after treatment of benign prostate hyperplasia (BPH) is becoming less common. This is a result of the changing patterns of BPH treatment. The purpose of the present research was to re-examine the clinical outcomes and importance of cT1a and cT1b PCa in a contemporary cohort after holmium laser enucleation of the prostate (HoLEP). All patients with newly diagnosed PCa after HoLEP were retrospectively identified. Pre- and postoperative prostate-specific antigen (PSA), biopsy history, pathological features and disease progression were examined. Patients were matched to a control group with benign pathology for outcome comparisons. The database consisted of 240 consecutive patients, aged 52-90years with prostate sizes from 25 to 375cm3. A total of 28 patients were identified with incidental PCa (14 cT1a and 14 cT1b). Median follow up was 11months and 13months for cT1a and cT1b, respectively. Hospitalization time, catheterization time, complications and functional outcomes were similar. Three patients with cT1b required additional treatment as a result of PSA progression. All other cancers are being closely followed. The functional benefits of HoLEP are well established. The incidental PCa detection rate of 11.7% shows the potential benefit of pathological analysis. Just 10.7% of these patients received additional treatment, but this might be significant as these patients would otherwise go untreated. The impact on disease-specific survival and progression requires a longer follow up.

AB - Incidental prostate cancer (PCa) after treatment of benign prostate hyperplasia (BPH) is becoming less common. This is a result of the changing patterns of BPH treatment. The purpose of the present research was to re-examine the clinical outcomes and importance of cT1a and cT1b PCa in a contemporary cohort after holmium laser enucleation of the prostate (HoLEP). All patients with newly diagnosed PCa after HoLEP were retrospectively identified. Pre- and postoperative prostate-specific antigen (PSA), biopsy history, pathological features and disease progression were examined. Patients were matched to a control group with benign pathology for outcome comparisons. The database consisted of 240 consecutive patients, aged 52-90years with prostate sizes from 25 to 375cm3. A total of 28 patients were identified with incidental PCa (14 cT1a and 14 cT1b). Median follow up was 11months and 13months for cT1a and cT1b, respectively. Hospitalization time, catheterization time, complications and functional outcomes were similar. Three patients with cT1b required additional treatment as a result of PSA progression. All other cancers are being closely followed. The functional benefits of HoLEP are well established. The incidental PCa detection rate of 11.7% shows the potential benefit of pathological analysis. Just 10.7% of these patients received additional treatment, but this might be significant as these patients would otherwise go untreated. The impact on disease-specific survival and progression requires a longer follow up.

KW - Benign prostate hyperplasia

KW - Holmium laser enucleation of the prostate

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=79959543602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959543602&partnerID=8YFLogxK

U2 - 10.1111/j.1442-2042.2011.02776.x

DO - 10.1111/j.1442-2042.2011.02776.x

M3 - Article

C2 - 21592233

AN - SCOPUS:79959543602

VL - 18

SP - 543

EP - 547

JO - International Journal of Urology

JF - International Journal of Urology

SN - 0919-8172

IS - 7

ER -